News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
268,213 Results
Type
Article (13924)
Company Profile (102)
Press Release (254187)
Multimedia
Podcasts (51)
Webinars (12)
Section
Business (88116)
Career Advice (465)
Deals (15359)
Drug Delivery (67)
Drug Development (36634)
Employer Resources (49)
FDA (6315)
Job Trends (6211)
News (150365)
Policy (14070)
Tag
Academia (441)
Accelerated approval (4)
Adcomms (6)
Allergies (41)
Alliances (23314)
ALS (42)
Alzheimer's disease (412)
Antibody-drug conjugate (ADC) (54)
Approvals (6372)
Artificial intelligence (136)
Autoimmune disease (10)
Automation (5)
Bankruptcy (150)
Best Places to Work (4370)
BIOSECURE Act (9)
Biosimilars (67)
Biotechnology (40)
Bladder cancer (24)
Brain cancer (19)
Breast cancer (106)
Cancer (822)
Cardiovascular disease (86)
Career advice (409)
Career pathing (12)
CAR-T (30)
CDC (3)
Cell therapy (104)
Cervical cancer (5)
Clinical research (31225)
Collaboration (435)
Compensation (200)
Complete response letters (18)
COVID-19 (765)
CRISPR (28)
C-suite (178)
Cystic fibrosis (45)
Data (916)
Denatured (16)
Depression (16)
Diabetes (96)
Diagnostics (1335)
Digital health (2)
Diversity (2)
Diversity, equity & inclusion (14)
Drug discovery (70)
Drug pricing (80)
Drug shortages (12)
Duchenne muscular dystrophy (48)
Earnings (32537)
Editorial (14)
Employer branding (4)
Employer resources (44)
Events (37999)
Executive appointments (467)
FDA (6910)
Friedreich's ataxia (2)
Frontotemporal dementia (1)
Funding (283)
Gene editing (46)
Generative AI (9)
Gene therapy (115)
GLP-1 (379)
Government (1325)
Grass and pollen (3)
Guidances (77)
Healthcare (3571)
Huntington's disease (5)
IgA nephropathy (19)
Immunology and inflammation (43)
Immuno-oncology (2)
Indications (19)
Infectious disease (804)
Inflammatory bowel disease (59)
Inflation Reduction Act (7)
Influenza (14)
Intellectual property (63)
Interviews (59)
IPO (5903)
IRA (31)
Job creations (2055)
Job search strategy (373)
Kidney cancer (7)
Labor market (18)
Layoffs (190)
Leadership (4)
Legal (3441)
Liver cancer (20)
Lung cancer (111)
Lymphoma (69)
Machine learning (4)
Management (16)
Manufacturing (206)
MASH (40)
Medical device (1288)
Medtech (1290)
Mergers & acquisitions (9722)
Metabolic disorders (308)
Multiple sclerosis (26)
NASH (14)
Neurodegenerative disease (32)
Neuropsychiatric disorders (10)
Neuroscience (640)
NextGen: Class of 2025 (1588)
Non-profit (597)
Now hiring (11)
Obesity (173)
Opinion (129)
Ovarian cancer (27)
Pain (66)
Pancreatic cancer (27)
Parkinson's disease (52)
Partnered (7)
Patents (148)
Patient recruitment (44)
Peanut (12)
People (29193)
Pharmaceutical (64)
Pharmacy benefit managers (14)
Phase I (8128)
Phase II (13200)
Phase III (11865)
Pipeline (664)
Policy (96)
Postmarket research (1401)
Preclinical (3264)
Press Release (25)
Prostate cancer (62)
Psychedelics (9)
Radiopharmaceuticals (125)
Rare diseases (204)
Real estate (2642)
Recruiting (17)
Regulatory (10277)
Reports (14)
Research institute (568)
Resumes & cover letters (55)
Rett syndrome (1)
RNA editing (4)
RSV (9)
Schizophrenia (44)
Series A (53)
Series B (23)
Service/supplier (3)
Sickle cell disease (35)
Special edition (6)
Spinal muscular atrophy (77)
Sponsored (7)
Startups (1636)
State (2)
Stomach cancer (3)
Supply chain (36)
Tariffs (43)
The Weekly (33)
Vaccines (178)
Venture capital (19)
Weight loss (102)
Women's health (10)
Worklife (4)
Date
Today (30)
Last 7 days (141)
Last 30 days (659)
Last 365 days (11181)
2025 (6071)
2024 (12501)
2023 (14246)
2022 (19556)
2021 (20068)
2020 (19032)
2019 (14885)
2018 (11713)
2017 (13889)
2016 (13129)
2015 (15472)
2014 (12419)
2013 (10592)
2012 (11395)
2011 (11923)
2010 (10888)
Location
Africa (314)
Alabama (16)
Alaska (1)
Arizona (61)
Arkansas (3)
Asia (20366)
Australia (2635)
California (2163)
Canada (1087)
China (339)
Colorado (88)
Connecticut (87)
Delaware (77)
Europe (39889)
Florida (422)
Georgia (46)
Hawaii (1)
Idaho (9)
Illinois (245)
India (16)
Indiana (164)
Iowa (1)
Japan (140)
Kansas (62)
Kentucky (16)
Louisiana (2)
Maine (2)
Maryland (311)
Massachusetts (1854)
Michigan (35)
Minnesota (112)
Mississippi (1)
Missouri (23)
Montana (8)
Nebraska (6)
Nevada (12)
New Hampshire (6)
New Jersey (959)
New Mexico (7)
New York (642)
North Carolina (459)
North Dakota (2)
Northern California (897)
Ohio (55)
Oklahoma (4)
Oregon (16)
Pennsylvania (521)
Puerto Rico (9)
Rhode Island (10)
South America (504)
South Carolina (5)
Southern California (913)
Tennessee (42)
Texas (296)
United States (8929)
Utah (45)
Virginia (104)
Washington D.C. (38)
Washington State (143)
West Virginia (1)
Wisconsin (22)
268,213 Results for "marinus pharmaceuticals".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Layoffs
Marinus Pharmaceuticals Lays Off 45% of Employees
The November layoffs are the second known workforce reduction this year for Marinus Pharmaceuticals, which previously announced disappointing Phase III results for ganaxolone in two clinical trials.
November 14, 2024
·
1 min read
·
Angela Gabriel
Press Releases
Immedica to Acquire Biopharmaceutical Company Marinus Pharmaceuticals, Inc.
December 30, 2024
·
11 min read
Drug Development
Marinus Pharmaceuticals Announces Key Business Updates for Tuberous Sclerosis Complex Program
Marinus Pharmaceuticals, Inc. today announced completion of enrollment in the global Phase 3 TrustTSC trial evaluating oral ganaxolone for the treatment of seizures associated with tuberous sclerosis complex (TSC) in children and adults.
May 17, 2024
·
7 min read
Pharm Country
Marinus Pharmaceuticals to Present at the RBC Capital Markets 2024 Global Healthcare Conference
Marinus Pharmaceuticals, Inc. today announced that Scott Braunstein, M.D., Chairman and Chief Executive Officer, will be participating in a fireside chat at the RBC Capital Markets 2024 Global Healthcare Conference.
May 2, 2024
·
1 min read
Business
Marinus Pharmaceuticals Provides Business Update and Reports First Quarter 2024 Financial Results
Marinus Pharmaceuticals, Inc., a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, reported business highlights and financial results for the first quarter ended March 31, 2024.
May 8, 2024
·
14 min read
Pharm Country
Marinus Pharmaceuticals to Present at Upcoming March 2024 Investor Conferences
Marinus Pharmaceuticals, Inc., a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, announced that management will present at and participate in the following conferences in March.
February 21, 2024
·
1 min read
Pharm Country
Marinus Pharmaceuticals Comments on Patent Challenge by Ovid Therapeutics Inc. and Provides Update on Marinus’ Post Grant Review
Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to developing and commercializing innovative therapeutics to treat seizure disorders, today affirmed its commitment to defending its patent portfolio amidst an Inter Partes Review (IPR) challenge of U.S. Patent 11,110,100 from Ovid Therapeutics, Inc. filed on March 26, 2024.
March 27, 2024
·
7 min read
Drug Development
Marinus Pharmaceuticals Announces Topline Results from Phase 3 RAISE Trial of IV Ganaxolone in Refractory Status Epilepticus
Marinus Pharmaceuticals today announced topline results from the Phase 3 double-blind, randomized, placebo-controlled RAISE trial (NCT04391569) evaluating the safety and efficacy of intravenous (IV) ganaxolone for the treatment of refractory status epilepticus (RSE).
June 17, 2024
·
11 min read
Business
Marinus Pharmaceuticals to Provide Business Update and Report First Quarter 2024 Financial Results on May 8, 2024
Marinus Pharmaceuticals, Inc. today announced that it plans to release financial results for the first quarter ended March 31, 2024 before market open on May 8, 2024.
May 1, 2024
·
1 min read
Pharm Country
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - April 05, 2024
Marinus Pharmaceuticals, Inc., a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, announced the grant of inducement awards to two new employees.
April 5, 2024
·
3 min read
1 of 26,822
Next
